IOVANCE BIOTHERAPEUTICS, INC. Accrued Liabilities, Current
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Accrued Liabilities, Current of $77.96 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $77.96M.
- 2026-03-31: Accrued Liabilities, Current $88.07M.
- 2025-12-31: Accrued Liabilities, Current $111.16M.
- 2025-09-30: Accrued Liabilities, Current $87.27M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $77.96M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $88.07M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $111.16M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $87.27M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $89.08M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $84.70M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $81.94M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $74.82M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $61.79M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $46.44M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $69.41M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $61.21M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $46.62M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $43.09M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $52.30M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $47.82M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $37.70M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $48.91M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $56.77M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $45.97M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $34.19M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $35.77M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $35.07M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $32.40M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $38.79M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $22.50M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $16.27M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $16.32M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $13.57M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $8.49M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $11.66M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $10.66M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $8.99M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $8.11M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $8.36M 10-K · filed 2019-02-28 | $8.66M 10-K · filed 2018-03-12 |
| 2017-09-30 | $5.62M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $5.17M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $3.33M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $4.11M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $2.97M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $3.88M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $690.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $672.00K 10-K · filed 2017-03-09 | $586.00K 10-K · filed 2016-03-11 |
| 2015-09-30 | $1.61M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $623.77K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $717.85K 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $328.00K 10-K · filed 2016-03-11 | $327.85K 10-K · filed 2015-03-16 |
| 2013-12-31 | $1.52M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |